-- Launch Expected in H1 2022 -- SAN CARLOS, Calif. , Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that TAVNEOS ® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult
SAN CARLOS, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: 40th Annual J.P. Morgan Healthcare Conference Wednesday, January 12 at
SAN CARLOS, Calif. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS
SAN CARLOS, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: Stifel 2021 Virtual Healthcare Conference Fireside Chat Wednesday,
-- U.S. Food & Drug Administration (FDA) approves TAVNEOS TM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan ; European CHMP opinion expected this month -- -- Pipeline advances: Company intends to meet with FDA on path
SAN CARLOS, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021 and American College of Rheumatology (ACR)
MOUNTAIN VIEW, Calif. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021 . ChemoCentryx executive management will host a conference call and
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the appointment of Rita I. Jain , M.D., as Executive Vice President, Chief Medical
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif. , Oct. 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the U.S.
Approved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis SAN CARLOS, Calif. , Sept. 27, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry
